Any News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016
|
|
- Mercy Richardson
- 5 years ago
- Views:
Transcription
1 Any News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016
2 Yes! Age disparities vary by tumor subtype Genomic risk prediction data in young women Adjuvant systemic therapy considerations for young women
3 Hazard Ratio Young Women Are More Likely to Die in NCCN All Tumors Luminal A Luminal B Triple Negative N=17,575 N=7738 N=5149 N=2886 Adjusted for race/ethnicity, insurance, employment, center, education, treatment, stage at diagnosis, grade, year of diagnosis, and detection method (symptomatic or Screen) Partridge et al, JCO 2016
4 Breast Cancer Subtypes by Increasing Age HER2+ HR+/HER2+ * TNBC HR+/HER2- * Keegan et al, BCR, 2012
5 Hazard Ratio Young Women Are More Likely to Die 3,50 3,00 2,50 2,00 1,50 1,00 0,50 0,00 HER2 type N= from Luminal A Tumors Luminal A N=7738 1,7 1 Luminal B N=5149 1,2 1 1 Triple Negative N=2886 Adjusted for race/ethnicity, insurance, employment, center, education, treatment, stage at diagnosis, grade, year of diagnosis, and detection method (symptomatic or screen) 1,3 1 Partridge et al, JCO 2016
6 TAILORx RS < 10 Sparano et al, NEJM, 2015
7 MINDACT Cardoso et al, NEJM, 2016
8 HER2+: BCIRG-006 Disease Free Survival Final Analysis(10.3yrs) % alive and disease-free 1 0,9 0,8 0,7 0,6 0,5 0,4 AC-T AC-TH TCH Patients Events HR (95% C.I.) P (reference) ( ) < ( ) Trastuzumab-containing regimens remain superior at 10y follow-up No formal comparison of anthracycline containing vs not G3/4 CHF: 21 vs 4 Despite benefits of trastuzumab, 25% of patients still recur by 10 years still room for improvement! 74.6% 73.0% 67.9% Time (months) Slamon et al, SABCS 2015
9 ALTTO Trial: DFS Analysis No added benefit from Lapatinib MFU = 4.5 yrs **p-value required for statistical significance * * 97.5% CI ** Piccart et al, NEJM 2016
10 Can We Improve in the Adjuvant HER2+ Setting? ExteNet: Study Design HER2+ breast cancer (local) Prior adjuvant trastuzumab & chemotherapy Lymph node /+ or residual invasive disease after neoadjuvant therapy ER/PR + or 25% of patients may still recur despite HER2 therapy. HERA did not support longer duration Trastuzumab. Primary endpoint: invasive disease-free survival (idfs) at 2 years (4 years after treatment completion) Complicated study with many amendments 1:1 randomization Neratinib x 1 year 240mg/day Placebo x 1 year Part A Part B Part C 2-year follow-up for idfs 5-year follow-up for idfs 5 + year survival Chan et al, ASCO 2015
11 ExteNet Primary Endpoint: Invasive DFS (ITT) Disease-free survival (%) P-value = HR (95% CI) = 0.67 ( ) 97.8% 95.6% Months after randomization Neratinib Placebo 93.9% 91.6% 2.5% absolute differenc e 40% grade 3 diarrhea Chan et al, ASCO 2015
12 S U R G E R Y N=4800 Central confirmation of HER2 status APHINITY Schema ACT or TCH trastuzumab + pertuzumab* x 1 year ACT or TCH negative Population: Node + or high risk node trastuzumab + placebo* x 1 year *antibody therapy starts with taxane
13 AC-TH TCH HER2+: Standard Regimens for Moderate to High Risk Disease Role of adjuvant pertuzumab? Based on results in preoperative setting without any DFS or OS data Included in NCCN guidelines as a footnote Not ready for routine use outside of selected patients as neoadjuvant therapy I don t think regimen choice here should vary by age
14 Preoperative Use of Pertuzumab FDA accelerated approval to pertuzumab in neoadjuvant setting 11/2013 as THP -> FEC or AC, or TCHP Approval based on NEOSPERE data, metastatic survival advantage, and completion of adjuvant trial NEOSPERE underpowered to determine if PFS predicts DFS/OS; await APHINITY Preoperative THP best reserved for patients at high risk of recurrence who need downstaging (e.g. stage IIB and III disease)
15 HER2+ ER+ or ER- Node Negative < 3 cm Accrual N=406 Less than 20% had T1a 50% had T1c or T2 APT Trial Study Design Enroll P T P T P T P T P T P T PACLITAXEL 80 mg/m 2 + TRASTUZUMAB 2 mg/kg x 12 T T T T T T T T T T T T T FOLLOWED BY 13 EVERY 3 WEEK DOSES P T P T P T OF TRASTUZUMAB (6 mg/kg)* *Dosing could alternatively be 2 mg/kg IV weekly for 40 weeks ** Radiation and hormonal therapy was initiated after completion of paclitaxel P T P T P T Tolaney et al, NEJM 2015
16 All patients APT Disease-Free Survival Disease-Free Survival (Probability) year DFS Time (Months) 95% Conf. Interval 98.7% 97.6% to 99.8% Poisson p-value: < events; only 2 distant and 4 local-regional recurrences Number at risk Tolaney et al, NEJM 2015
17 Cardiac Safety of Trastuzumab without Anthracycline: APT Trial Majority had stable LVEF during treatment 3.2%: asymptomatic drop in LVEF requiring trastuzumab hold 0.5%: grade 3 LV dysfunction, all had risk factors for cardiac dysfunction Dang et al, JAMA Oncol 2016
18 Stage I HER2+* ER+ or ER- PS 0-1 Adequate organ fx N=500 ATEMPT Trial Schema R Trastuzumab-DM1 q3weeks X17 *HER2-positive defined as IHC 3+ or FISH 2.0; will be confirmed by central HER2 testing prior to study enrollment Adjuvant endocrine therapy can be initiated after completion of 12 weeks of therapy Adjuvant radiation therapy can be administered concurrently with study treatment. 3 1 N=375 Paclitaxel + Trastuzumab x12 Trastuzumab q3weeks x13 N=125 PI: Sara Tolaney, MD, MPH
19 A Sequential Antracycline-Taxane Combination is the Standard of Care for Moderate-Risk TNBC NSABP-B30 AC-T x 8 vs AT x 4 vs TAC x 6 Swain SM et al. N Engl J Med 2010;362: POSSIBLE REGIMENS AC-paclitaxel (dose dense) AC-weekly paclitaxel AC-docetaxel (every 3 weeks) FEC-docetaxel
20 2016 Is Anthracycline Necessary for TNBC? ABC Trials (TC/TAC, B-46I, B-49) Node+ or High Risk Node-Negative ARM 1 (TaxAC Options) ARM 2 (TC) A TAC q 3 wk TC q 3 wk B AC q 3 wk PTX q 1 wk Arm 1 Options Per Study USOR A only NSABP B-46I/USOR A only C AC q 2 wk PTX q 1 wk NSABP B-49 - investigator choice 1A-1D Endocrine therapy for ER+ or PgR+ patients for minimum of 5 years AC q 2 wk D PTX q 2 wk Designed to prove non-inferiority of non-anthracycline arm Blum et al, ASCO
21 Alive and Inv. Disease-free (%) ABC Trials: Invasive Disease Free Survival yr Treatment N Events IDFS TC % TaxAC % HR=1.23, 95% CI ( ) P= Years from Randomization Δ=2.5% Observed HR on initial 334 events Exceeded pre-specified threshold for futility (> 1.18) > not non-inferior Blum et al, ASCO 2016
22 2016 ABC Trials: IDFS by Hormone and Nodal Status Exploratory Analysis Pts Events 4 yr IDFS 4 yr IDFS HR (95% CI) TaxAC TC TaxAC TC TaxAC TC Delta ER/PgR (-) N % 1.31 ( ) 1-3 N % 1.58 ( ) 4+ N % 1.34 ( ) ER or PgR (+) N % 0.69 ( ) 1-3 N % 1.14 ( ) 4+ N % 1.46 ( ) Suggests all groups aside from ER+ N0 benefit from A-containing regimens, especially ER- N+ Blum et al, ASCO
23 Eligibility: HER2- with residual disease after A- and T- containing NAC DFS Adjuvant Capecitabine? OS Dose: 2,500 mg/m2/day, D1-14, x 8 cycles (24 wks) Toi et al, SABCS 2015
24 Randomized Trials of Preoperative Platinum Chemotherapy for TNBC GeparSixto Schema CALGB Schema Sikov et al. JCO 2015;33:13-21; von Minckwitz et al. Lancet Oncology, May 2014 GerparSixto pcr: platinum vs not CALGB pcr: platinum vs not
25 Sikov et al. SABCS 2015; von Minckwitz et al. SABCS 2015 Does Addition of Preoperative Platinum Improve Survival Outcomes for TNBC? GeparSixto 3Y DFS: Improved with Carbo CALGB Y EVS: Not Improved with Carbo Mixed results on survival benefits from preop platinum in TNBC Achieving pcr is a good surrogate for long-term outcomes on a patient level No evidence that pcr rates can be used as a surrogate for survival on a trial level to compare regimens in TNBC
26 Is Carboplatin Ready for Primetime in Unselected TNBC in the Adjuvant or Neoadjuvant Setting? NO Need definitive study showing improvement in DFS and/or OS If platinum is ultimately used, should it be added to standard therapy or substituted for one or more drugs? Are there triple negative subtypes that are particularly sensitive to platinum, ie biomarker driven?
27 Preoperative Cisplatin As Preoperative Therapy in Patients With BRCA1 Mutations 107 patients with BRCA1 mutations Stage I-III disease Treatment: Preoperative Cisplatin 75 mg/m 2 q 3 weeks x 4 Mastectomy Path CR defined as no invasive tumor in breast/nodes Pathologic complete response = 61% Byrski et al. Breast Cancer Research and Treatment 2014 and Arun et al, JCO 2011
28 INFORM: preop cisplatin vs AC for BRCA 1/2 carriers Schema: Randomized Phase 2: 166 patients Stage II/III BC with BRCA1 or 2 mutation N = 170; approximately 60 enrolled Multicenter study AC x 4 Cis x 4 Designed to show 20% improvement in pcr with cisplatin over AC Principal Investigators: Nadine Tung and Judy Garber S U R G E R Y Or Biopsy B Additional Chemo
29 Do We Have Sufficient Data To Incorporate Platinum in Early Treatment of BRCA Associated TNBC? May never have large, definitive trial Mounting evidence in neoadjuvant and metastatic settings Biology is consistent with clinical observations Probably ready or close to it ideally would like to see results of neoadjuvant INFORM trial How do we do it? Add to standard? Substitute for one or more agents?
30 Ovarian Suppression through chemotherapy: POEMS/S0230 Standard cyclophosphamide containing (neo)adjuvant chemotherapy Premenopausal Stage I, II, IIIA ER-/PR- Breast Cancer Under Age 50 Stratified by age and chemotherapy regimen Randomization Standard cyclophosphamide containing (neo)adjuvant chemotherapy + goserelin Moore et al, ASCO 2014, NEJM 2015
31 POEMS/S0203 Moore et al, ASCO 2014, NEJM 2015
32 POEMS Ovarian Failure Standard Chemotherapy Chemotherapy + Goserelin Ovarian failure at 2 years 15/69 = 22% 5/66 = 8% Logistic Regression Results: Analysis Odds Ratio 95% CI p-value One-sided Two-sided Univariate p=.01 p=.03 Stratified* p=.02 p=.04 Multivariate * p=.04 p=.08 *Accounting for age and regimen through stratification ( Stratified ) or covariate ( Multivariate ) adjustment, respectively Courtesy of H. Moore
33 POEMS Pregnancy Standard Chemotherapy n=113 Chemotherapy + Goserelin n=105 Adjusted OR Adjusted P-value Attempted pregnancy 18 (16%) 25 (24%) p=.12 Achieved pregnancy 12 (11%) 22 (21%) 2.45 p=.03 Patients with > 1 delivery Delivery or ongoing pregnancy Total number of babies Ongoing pregnancies Total adverse events Miscarriages Elective termination Delivery complication 8 (7%) 10 (9%) (15%) 19 (18%) p=.05 p=.04 Courtesy of H. Moore
34 Ovarian Suppression Through Treatment: RCTs Investigator Bawady Sverrisdottir Del M astro Leonard Gerber Munster Elgindy SWOG 0230 Year , update NEJM Patients (n) Study type Phase II RCT Substudy from combined analysis of 4 RCTs using core protocol Phase III RCT Phase III RCT (abstract only) Phase II RCT Phase III RCT Phase II RCT Phase III RCT Treatment CT + goserelin vs TAM^ +/-CT CT + triptorelin vs. CT + goserelin vs. CT + goserelin vs. CT + triptorelin vs. Delayed CT : CT + goserelin vs. arms CT Goserelin +/-CT CT CT CT CT CT + triptorelin vs. CT Goserelin/TAM +/-CT TAM +/-CT CT Early CT : CT + triptorelin + cetrorelix β vs. CT Median age [range] 30 [26-33] 45 [29-55] 39 [24-45] NR 37 [26-47] 39 [21-43] 33 [18-40] 38 [25-49] Premenopausal Regular LMP <6 months Actively Regular menses in Regular Regular Regular menstruation LMP < 6 weeks definition menstruation prior to study menstruation during 12 months menstruation menstruation ( 3 ( 3 consecutive pre-randomisation FSH <10 IU/L entry, including 6 weeks pre-ct preceding surgery FSH <15 in periods in 6 months, periods within or FSH & E2 in irregular cycles follicular phase lasting 2 days, days apart days) premenopausal range FSH <40 IU/L %ER+ NR 45% 81% NR 0% 73% 0% 0% Marker of fertility preservation Resumption of menstruation or spontaneous ovulation Resumption of menstruation Resumption of menstruation Resumption of menstruation Resumption of menstruation Resumption of menstruation Resumption of menstruation Resumption of menstruation, postmenopausal FSH, pregnancy Primary Rate of POF (no Recovery of Rate of CIA (no Rate of Rate of normal Uninterrupted or Rate of regular Rate of ovarian endpoint menstruation/ menstruation menstruation and amenorrhea 12 ovarian function at restored menstruation at 12 failure spontaneous post-menopausal months after start 6 months post-ct menstruation during months after (amenorrhea) at 2 ovulation) 3 months post-ct FSH/E2 levels) for 12 months post-ct of CT f/u of at least 2 years post CT completion of CT years, FSH Median f/u [range] NR [3-8 months] NR 12 months post-ct NR 6, 12, 24, 48 months post-ct 18 months [5-43 months] after CT NR All patients followed for at least 12 months Planned f/u at 1,2 and 5 years Rate of 90% (goserelin) At 6 months post 91.1% (triptorelin) NR 70% (goserelin) 88.5% (triptorelin) At 12 months post-ct 8% (goserelin) vs. recovery of vs. 33% ET cessation : vs. 74.1% (control) No statistically vs. 56.7% vs. 90.5% (control) Delayed CT: 22% (control) menstruation: (control), p< % (goserelin) vs. 10% (control), p<0.001 significant difference between (control) Trial stopped early for futility 72% (triptorelin) vs. 52% (control), p=0.15 Trial stopped prior 13% (TAM), 7% goserelin + TAM), treatment arms (further details not Early CT: 60% (triptorelin + to full accrual due to funding issues p= published) cetrorelix) vs 48% (control), p=0.39 Pregnancies No data on No data on 3 pregnancies in No data on 1 pregnancy in 2 pregnancies in 3 pregnancies, one in 21% vs. 11% pregnancies pregnancies triptorelin arm, 1 in pregnancies control arm each group control arm early CT + triptorelin + cetrorelix arm, 1 in early CT control arm pregnancy favouring goserelin Adapted from N. Turner et al., Ann Oncol 2013
35 Ovarian Suppression Through Treatment: 9 RCTs Investigator Bawady Sverrisdottir Del M astro Leonard Gerber Munster Elgindy SWOG 0230 Year , update NEJM Patients (n) Study type Phase II RCT Substudy from combined analysis of 4 RCTs using core protocol Phase III RCT Phase III RCT (abstract only) Phase II RCT Phase III RCT Phase II RCT Phase III RCT Treatment CT + goserelin vs TAM^ +/-CT CT + triptorelin vs. CT + goserelin vs. CT + goserelin vs. CT + triptorelin vs. Delayed CT : CT + goserelin vs. arms CT Goserelin +/-CT CT CT CT CT CT + triptorelin vs. CT Goserelin/TAM +/-CT TAM +/-CT CT Early CT : CT + triptorelin + cetrorelix β vs. CT Median age [range] 30 [26-33] 45 [29-55] 39 [24-45] NR 37 [26-47] 39 [21-43] 33 [18-40] 38 [25-49] Premenopausal Regular LMP <6 months Actively Regular menses in Regular Regular Regular menstruation LMP < 6 weeks definition 12 months menstruation menstruation ( 3 ( 3 consecutive pre-randomisation FSH Meta-analysis <10 IU/L entry, including 6 weeks ongoing pre-ct preceding surgery FSH <15 in periods in 6 months, periods within or FSH & E2 in irregular cycles follicular phase lasting 2 days, days apart FSH <40 IU/L days) premenopausal range %ER+ NR 45% 81% NR 0% 73% 0% 0% Marker of Resumption No of hint Resumption of of a Resumption safety of problem Resumption of Resumption of Resumption of Resumption of Resumption of fertility preservation menstruation or spontaneous ovulation menstruation menstruation menstruation menstruation menstruation menstruation menstruation, postmenopausal FSH, pregnancy Primary Rate of POF (no Recovery of Rate of CIA (no Rate of Rate of normal Uninterrupted or Rate of regular Rate of ovarian endpoint failure spontaneous Reasonable post-menopausal to consider months after start as 6 months an post-ct additional menstruation during months option after for (amenorrhea) at 2 ovulation) 3 FSH/E2 levels) for of CT f/u of at least 2 completion of CT years, FSH months preservation post-ct 12 months of post-ct menstrual functioning years post CT and fertility Median f/u NR [3-8 months] NR 12 months post-ct NR 6, 12, 24, months [5-43 NR Planned f/u at 1,2 [range] months post-ct months] after CT All patients followed for at least 12 months and 5 years Rate of 90% (goserelin) At 6 months post 91.1% (triptorelin) NR 70% (goserelin) 88.5% (triptorelin) At 12 months post-ct 8% (goserelin) vs. recovery of vs. 33% ET cessation : vs. 74.1% (control) No statistically vs. 56.7% vs. 90.5% (control) Delayed CT: 22% (control) menstruation: (control), p< % (goserelin) vs. 10% (control), p<0.001 significant difference between (control) Trial stopped early for futility 72% (triptorelin) vs. 52% (control), p=0.15 Trial stopped prior 13% (TAM), 7% goserelin + TAM), treatment arms (further details not Early CT: 60% (triptorelin + to full accrual due to funding issues p= published) cetrorelix) vs 48% (control), p=0.39 Pregnancies No data on No data on 3 pregnancies in No data on 1 pregnancy in 2 pregnancies in 3 pregnancies, one in 21% vs. 11% pregnancies pregnancies triptorelin arm, 1 in pregnancies control arm each group control arm early CT + triptorelin + cetrorelix arm, 1 in early CT control arm pregnancy favouring goserelin Adapted from N. Turner et al., Ann Oncol 2013
36 THANK YOU!
The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017 Relative Risk HER2-positive Breast
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2018 HER2-positive Breast Cancer Adjuvant
More informationTreatment of Early-Stage HER2+ Breast Cancer
Treatment of Early-Stage HER2+ Breast Cancer Chau T. Dang, MD Chief, MSK Westchester Medical Oncology Service Breast Medicine Service Memorial Sloan Kettering Cancer Center Disclosures I have research
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationPRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients
PRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients Amelia B. Zelnak, M.D., M.Sc. Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute
More informationTreatment of HER2+ and Triple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Boston, USA
Treatment of HER2+ and Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Boston, USA ewiner@partners.org Disclosure Disclosure Consultant Tessaro, Leap, Genentech Off Label/Investigational
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationNeoadjuvantTreatment In BC When, How, Who?
NeoadjuvantTreatment In BC When, How, Who? Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service, MSKCC Professor of Medicine, Weill Cornell Medical College President, ASCO 15 Potential Benefits Of
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center
Novel Preoperative Therapies for HER2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Key Findings to Date in the Neoadjuvant Therapy of HER2+
More informationSystemic Therapy for Locally Advanced Breast Cancer
Systemic Therapy for Locally Advanced Breast Cancer Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology National University Cancer Institute, Singapore Clinical Care Senior Principal
More informationTriple negative breast cancer -neoadjuvant and adjuvant systemic therapy
Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy Sung-Bae Kim, MD, PhD Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea DISCLOSURE
More informationTreatment of HER2+ and Triple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Boston, USA
Treatment of HER2+ and Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Boston, USA ewiner@partners.org Disclosure I have nothing to disclose. Off Label/Investigational Discussion
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationLocally Advanced Breast Cancer: Systemic and Local Therapy
Locally Advanced Breast Cancer: Systemic and Local Therapy Joseph A. Sparano, MD Professor of Medicine & Women s Health Albert Einstein College of Medicine Associate Chairman, Department of Oncology Montefiore
More informationNon-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationTreatment of Early Stage HER2-positive Breast Cancer (One size does not fit all)
Treatment of Early Stage HER2-positive Breast Cancer (One size does not fit all) 8 November 2014 Edward H. Romond, M.D. Professor of Medicine Lucille Parker Markey Cancer Center University of Kentucky
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationEarly Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center
SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10
More information(NEO-)ADJUVANT THERAPY FOR HER-2+ EBC
(NEO-)ADJUVANT THERAPY FOR HER-2+ EBC Rebecca Dent, MD FRCP (Canada) Senior Consultant, National Cancer Center Singapore Associate Professor, Duke-NUS www.abc-lisbon.org When to question a pathology report?
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Dilemmas in Adjuvant Chemotherapy Is adjuvant chemotherapy effective in ER+
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More information(Neo)Adjuvant Chemotherapy and biological Agents (essentials in HER2 and TN early breast cancer)
(Neo)Adjuvant Chemotherapy and biological Agents (essentials in HER2 and TN early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Neoadjuvant
More informationTNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017
TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017 The problem with TNBC 1. Generally more aggressive 2. ONLY chemotherapy 3. No other
More informationBreast : ASCO Abstracts for Review
Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal
More informationExiste-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon
Existe-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon In 25 results of 4 Adjuvant Herceptin trials have definitively
More informationPositive HER-2 tumor. How to incorporate the new drugs into neoadjuvance
Oncology Department Vall d Hebron University Hospital Barcelona. Spain Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance Javier Cortés June/2013 MD Anderson experience Buzdar et
More informationDR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA
Recent Advances of Docetaxel in Management of Breast Cancer DR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA 1 ADJUVANT
More informationASCO 2017 BREAST CANCER HIGHLIGHTS
Post-ASCO 24 th June 2017, Dolce La Hulpe, Belgium ASCO 2017 BREAST CANCER HIGHLIGHTS Martine J. Piccart-Gebhart, MD, PhD Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast
More information38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %
38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype
More informationImpact of BMI on pathologic complete response (pcr) following neo adjuvant chemotherapy (NAC) for locally advanced breast cancer
Impact of BMI on pathologic complete response (pcr) following neo adjuvant chemotherapy (NAC) for locally advanced breast cancer Rachna Raman, MD, MS Fellow physician University of Iowa hospitals and clinics
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationNadia Harbeck Breast Center University of Cologne, Germany
Evidence in Favor of Taxane Based Combinations and No Anthracycline in Adjuvant and Metastatic Settings Nadia Harbeck Breast Center University of Cologne, Germany Evidence in Favor of Taxane Based Combinations
More informationPoint of View on Early Triple Negative
Point of View on Early Triple Negative Valentina Rossi, MD UOSD Oncologia dei Tumori della Mammella Azienda Ospedaliera S.Camillo-Forlanini VRossi@scamilloforlanini.rm.it Outline Neoadjuvant Setting IPSY-2
More informationThe Expert Thoughts. Alessandra Fabi Oncologia Medica 1
The Expert Thoughts Alessandra Fabi Oncologia Medica 1 My Thoughts Neoadjuvant: from the lessons of the history Adjuvant: Escalation and De-escalation Advanced and HER2+ : field for immunomodulation Brain
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationSustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA
Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA The fascinating history of Herceptin 1981 1985 1987 1990 1992 1998 2000 2005 2006 2008 2011 Murine
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationTerapia sistemica neoadiuvante: in quali tumori? Quali risultati? Dott. Giacomo Pelizzari
Terapia sistemica neoadiuvante: in quali tumori? Quali risultati? Dott. Giacomo Pelizzari Neoadjuvant Treatment A window of opportunity Rational: Historically proposed to enable breast-conserving surgery
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationCáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Recurrence of HER2-positive breast cancer (A) Time to
More informationASCO and San Antonio Updates
ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs
More informationOPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER. Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx
OPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx ANTHRACYCLINES AND TAXANES ARE COMMONLY USED USED IN MOST REGIMENS
More informationBREAST CANCER RISK REDUCTION (PREVENTION)
BREAST CANCER RISK REDUCTION (PREVENTION) Articles Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More informationBreast Cancer: Chemotherapy and Novel Agents
North Carolina Oncology Association & South Carolina Oncology Society Joint Membership Meeting ~ February 26 27, 2010 The Ballantyne Resort ~ Charlotte, NC Breast Cancer: Chemotherapy and Novel Agents
More informationAdjuvant Endocrine Therapy in Premenopausal Patients
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Endocrine Therapy in Premenopausal Patients Adjuvant Endocrine Therapy in Premenopausal Patients www.agoonline.de
More informationUse of Ovarian Suppression and Ablation in Breast Cancer Treatment
Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation
More informationAdjuvant Chemotherapy TNBC & HER2 Subtype
Adjuvant Chemotherapy TNBC & HER2 Subtype 2015.08.15 Gun Min Kim Yonsei Cancer Center Division of Medical Oncology Department of Internal Medicine Yonsei University College of Medicine gmkim77@yuhs.ac
More information10/15/2012. Inflammatory Breast Cancer vs. LABC: Different Biology yet Subtypes Exist
Triple-Negative Breast Cancer: Optimizing Treatment for Locally Advanced Breast Cancer Beth Overmoyer MD Director, Inflammatory Breast Cancer Program Dana Farber Cancer Institute Overview Inflammatory
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationEARLY BREAST CANCER, HER2-POSITIVE
EARLY BREAST CANCER, HER2-POSITIVE CLINICAL CASE DISCUSSION Elżbieta Senkus Medical University of Gdańsk Gdańsk, Poland esmo.org DISCLOSURES Honoraria: Amgen, Astellas, AstraZeneca, Bayer, BMS, Celgene,
More informationSystemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
More information(Neo) Adjuvant systemic therapy for HER-2+ EBC
(Neo) Adjuvant systemic therapy for HER-2+ EBC F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESMO Board of Directors & NR Committee Chair ESO Breast Cancer Program
More informationFDA Briefing Document Oncologic Drugs Advisory Committee Meeting. September 12, sbla /51 Pertuzumab (PERJETA ) Applicant: Genentech, Inc.
/51 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting September 12, 2013 /51 Pertuzumab (PERJETA ) Applicant: Genentech, Inc. Disclaimer: The attached package contains background information
More informationAdjuvant chemotherapy in older breast cancer patients: how to decide?
Adjuvant chemotherapy in older breast cancer patients: how to decide? H. Wildiers University Hospitals Leuven Belgium Wildiers H, Kunkler I, Lancet Oncol 2007 Biganzoli L, Wildiers H, Lancet Oncol. 2012
More informationEARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino
EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT
More informatione-session 381 BCY3 - Highlights of the 3rd ESO-ESMO Breast Cancer in Young Women International Conference
Expert: Dr Olivia Pagani, Oncology Institute of Southern Switzerland, Lugano, Switzerland Discussant: Dr Fedro Alessandro Peccatori, European Institute of Oncology, Milan, Italy e-session 381 BCY3 - Highlights
More informationAssessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint
Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center of Northwestern University Classical
More informationIdeal neo-adjuvant Chemotherapy in breast ca. Dr Khanyile Department of Medical Oncology, University of Pretoria
Ideal neo-adjuvant Chemotherapy in breast ca Dr Khanyile Department of Medical Oncology, University of Pretoria When is neo-adjuvant Chemo required? Locally advanced breast ca: - Breast conservative surgery
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationNSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions
1 1 NSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health
More informationNon-anthracycline Adjuvant regimens in Early Breast Cancer. Yeesoo Chae, MD, PhD Medical Oncology Kyungpook National University Medical Center
Non-anthracycline Adjuvant regimens in Early Breast Cancer Yeesoo Chae, MD, PhD Medical Oncology Kyungpook National University Medical Center Contents Role of Anthracyclines in adjuvant treatment EBCTCG2012
More informationUpdates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer
Key Findings to Date in the Neoadjuvant Therapy of H2+ Breast Cancer Novel Preoperative Therapies for H2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive
More informationORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA
ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)
More informationAdjuvant Endocrine Therapy in Premenopausal Patients
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Endocrine Therapy in Premenopausal Patients Adjuvant Endocrine Therapy in Premenopausal Patients Version 2002: Scharl
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationCurrent and Future perspectives of HER2+ BC
2018.4.6 GBCC Satellite symposium Current and Future perspectives of HER2+ BC Jee Hyun Kim, M.D., Ph.D. Seoul National University Bundang Hospital Seoul National University College of Medicine Disclaimer
More informationAnthracyclines for Breast Cancer? Are Adjuvant Anthracyclines Dispensible? Needs to be Answered in a Large Prospective Trial
Anthracyclines for Breast Cancer? Are Adjuvant Anthracyclines Dispensible? Needs to be Answered in a Large Prospective Trial Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Dallas, TX Early Breast Cancer
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationA case of a BRCA2-mutated ER+/HER2 breast cancer during pregnancy
ESMO Preceptorship Programme Breast Cancer Lisbon 16,17 September 2016 Emanuela Risi Sandro Pitigliani Medical Oncology Department Hospital of Prato, Istituto Toscano Tumori, Prato, Italy A case of a BRCA2-mutated
More informationThe Three Ages of Systemic Adjuvant Therapy for EBC
The Three Ages of Systemic Adjuvant Therapy for EBC 1896-2018 Nicholas Wilcken Westmead Hospital Petersham Institute University of Sydney Questions to be answered (concentrating on chemotherapy) Why should
More informationNEOADJUVANT THERAPY FOR BREAST CANCER: LOCAL EXPERT OPINION AND RECENT EVIDENCE
NEOADJUVANT THERAPY FOR BREAST CANCER: LOCAL EXPERT OPINION AND RECENT EVIDENCE Dr. Joanne Chiu Medical Oncology Queen Mary Hospital The University of Hong Kong HONG KONG SURVEY FOR NEOADJUVANT THERAPY
More informationSt Gallen 2017 controversies & consensus
St Gallen 2017 controversies & consensus Shani Paluch-Shimon, MBBS, MSc Head, Breast Cancer Service for Young Women Breast Unit, Division of Oncology Sheba Medical Centre June 2017 St Gallen 2017 De-escalation
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationLecture 5. Primary systemic therapy: clinical and biological endpoints
Lecture 5 Primary systemic therapy: clinical and biological endpoints Valentina Guarneri, M.D., Ph.D. Primary systemic therapy in breast cancer Firstly introduced d into clinical i l practice in 70s for
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationESMO Breast Cancer Preceptorship Singapore November Special Issues in Treatment of Young Women with Breast Cancer
ESMO Breast Cancer Preceptorship Singapore November 2017 Special Issues in Treatment of Young Women with Breast Cancer Prudence Francis MD Peter MacCallum Cancer Centre Melbourne, Australia Conflict of
More information03/14/2019. GnRH Analogs for Fertility Preservation: What are the Data? Educational Objectives. Outline
GnRH Analogs for Fertility Preservation: What are the Data? AHN-JH SKCCC Current Topics in Breast Cancer Symposium Karen Lisa Smith MD MPH Assistant Professor Johns Hopkins Breast and Cancer Program March
More informationEndocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology
Endocrine Therapy in Premenopausal Breast Cancer Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Ovarian Ablation or Suppression vs. Not in ER + or ER UK Breast Cancer
More informationAdjuvant endocrine therapy (essentials in ER positive early breast cancer)
Adjuvant endocrine therapy (essentials in ER positive early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Picking optimal adjuvant endocrine
More informationDennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
More informationSYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
SYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER Sunil Shrestha 1*, Ji Yuan Yang, Li Shuang and Deepika Dhakal Clinical School of Medicine, Yangtze University, Jingzhou, Hubei Province, PR. China Department
More information(Neo-) Adjuvant chemotherapy and biological agents. Giuseppe Curigliano MD, PhD University of Milano and European Institute of Oncology
(Neo-) Adjuvant chemotherapy and biological agents Giuseppe Curigliano MD, PhD University of Milano and European Institute of Oncology Outline Neoadjuvant treatment in triple negative and HER2 positive
More information4, :00 PM 9:00 PM
Consensus or Controversy? Clinical Investigators Provide Their Perspectives on Practical Issues and Research Questions in the Management of Breast Cancer Robert W Carlson, MD John Crown, MD Charles E Geyer
More informationUpdate in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors
More informationIntroduction. Approximately 20% of invasive breast cancers
Introduction Approximately 2% of invasive breast cancers overexpress HER2 The current standard of care for neoadjuvant therapy is dual-targeted therapy with trastuzumab and pertuzumab plus chemotherapy
More informationPostoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital
Postoperative Adjuvant Chemotherapies Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Does Chemotherapy Work in Older Patients? ER : Chemotherapy vs nil Age
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More information